Mergers, acquisitions, in-licensing and out-licensing have dramatically increased in popularity as a revenue stream for life science organizations. This is due to both the length of time it can take to research a new product from the ground up, and the progressively crowded marketplace. The life sciences industry has experienced success through increased licensing, which has moved it from a secondary activity to a necessary measure to ensure a healthy bottom line.

C613execsummimgBig pharma, innovative biotechs and medical device companies have millions of dollars riding on the success of licensing deals. A deal gone wrong can mean massive debts and wasted resources on all sides. It’s crucial to be able to find a licensing partner you can trust, and to be able to search out and identify potential partnerships and valuable products.

ExL Events’ 2nd Due Diligence Summit for Life Sciences, convening in Boston on June 9-10, 2015, was designed after conducting extensive research with your peers and learning about challenges you face and the thought leaders who can help you solve them. This is an educational event focused on how to run a tight ship throughout the due diligence process by presenting you with experienced speaking faculty members from Pfizer, AstraZeneca, Boehringer Ingelheim, and more!

Download the brochure for a complete list of the dynamic interactive sessions, brand-new case studies and innovative tool kits you’ll want to use in 2015.

Want to know more? Download the executive summary from ExL Events’ inaugural forum for an in-depth look at the key findings and final thoughts from the event.

Register by April 24th to receive the early bird pricing and be sure to mention priority code C613PB. If you have any questions, feel free to email

  Print This Post Print This Post  

Comments are closed.